Laquinimod in Participants With Relapsing-Remitting Multiple Sclerosis with Avonex® Reference Arm

- Multiple Sclerosis
- Completed

Study Title: BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon ־²-1a (Avonexֲ®)

Teva Identifier: MS-LAQ-302 | EUDRACT 2007-005450-23

ClinicalTrials.gov Identifier: NCT00605215

Study Status: Completed

Trial Condition(s): Multiple Sclerosis

Interventions: Drug: laquinimod | Drug: placebo | Drug: Interferon ־²-1a (Avonexֲ®)

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult

Age Range: 18 Years to 55 Years

Trial Duration: 04/01/2008 - 12/01/2011

Phase: Phase 3

Study Type

Interventional